Silencing circular RNA circ_0054537 and upregulating microRNA-640 suppress malignant progression of renal cell carcinoma via regulating neuronal pentraxin-2 (NPTX2)

References

• Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–530.
   PubMed Web of Science ®Google Scholar
• Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–552.
   PubMed Web of Science ®Google Scholar
• Barth DA, Slaby O, Klec C, et al. Current concepts of non-coding RNAs in the pathogenesis of non-clear cell renal cell carcinoma. Cancers (Basel). 2019;11:10.
   Web of Science ®Google Scholar
• Rydzanicz M, Wrzesinski T, Bluyssen HA, et al. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett. 2013;341(2):111–126.
   PubMed Web of Science ®Google Scholar
• Vasudev NS, Selby PJ, Banks RE. Renal cancer biomarkers: the promise of personalized care. BMC Med. 2012;10:112.
   PubMed Web of Science ®Google Scholar
• Jin J, Sun H, Shi C, et al. Circular RNA in renal diseases. J Cell Mol Med. 2020;24(12):6523–6533.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Wang P, et al. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Mol Cancer. 2020;19(1):149.
   PubMed Web of Science ®Google Scholar
• Liu J, Li D, Luo H, et al. Circular RNAs: the star molecules in cancer. Mol Aspects Med. 2019;70:141–152.
   PubMed Web of Science ®Google Scholar
• He YH, Chen C, Shi Z. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma. J Cell Physiol. 2018;233(6):4458–4465.
   PubMed Web of Science ®Google Scholar
• Kumar S, Gonzalez EA, Rameshwar P, et al. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel). 2020;12:12.
   Web of Science ®Google Scholar
• Mehdi A, Riazalhosseini Y. Epigenome aberrations: emerging driving factors of the clear cell renal cell carcinoma. Int J Mol Sci. 2017;18:8.
   Web of Science ®Google Scholar
• Xing T, He H. Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res. 2016;28(1):80–91.
   PubMed Web of Science ®Google Scholar
• Li R, Luo S, Zhang D. Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of renal cell carcinoma through regulating cMet pathway. Gene. 2020;754:144811.
   PubMed Web of Science ®Google Scholar
• Zhai Z, Fu Q, Liu C, et al. Emerging roles of hsa-circ-0046600 targeting the miR-640/HIF-1alpha signalling pathway in the progression of HCC. Onco Targets Ther. 2019;12:9291–9302.
   PubMed Web of Science ®Google Scholar
• Tang C, Wang X, Ji C, et al. The role of mir-640: a potential suppressor in breast cancer via Wnt7b/beta-catenin signaling pathway. Front Oncol. 2021;11:645682.
   PubMed Web of Science ®Google Scholar
• Dong W, Liu J, Lv Y, et al. miR-640 aggravates intervertebral disc degeneration via NF-kappaB and WNT signalling pathway. Cell Prolif. 2019;52(5):e12664.
   PubMed Web of Science ®Google Scholar
• Wang GX, Pan JY, Wang YJ, et al. MiR-640 inhibition alleviates acute liver injury via regulating WNT signaling pathway and LRP1. Eur Rev Med Pharmacol Sci. 2020;24(17):8988–8996.
   PubMed Web of Science ®Google Scholar
• Harel S, Sanchez-Gonzalez V, Echavarria R, et al. Roles of miR-640 and zinc finger protein 91 (ZFP91) in angiopoietin-1-induced in vitro angiogenesis. Cells. 2020;9:7.
   Web of Science ®Google Scholar
• Zhou Y, Li XH, Zhang CC, et al. Hydrogen sulfide promotes angiogenesis by downregulating miR-640 via the VEGFR2/mTOR pathway. Am J Physiol Cell Physiol. 2016;310(4):C305–317.
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74(17):4796–4810.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Hafezi S, Rahmani M. Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers (Basel). 2021;13:6.
   Web of Science ®Google Scholar
• Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12.
   PubMed Web of Science ®Google Scholar
• Pego ER, Fernandez I, Nunez MJ. Molecular basis of the effect of MMP-9 on the prostate bone metastasis: a review. Urol Oncol. 2018;36(6):272–282.
   PubMed Web of Science ®Google Scholar
• Chen RX, Chen X, Xia LP, et al. N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10(1):4695.
   PubMed Web of Science ®Google Scholar
• Yang Y, Lane AN, Ricketts CJ, et al. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. Plos One. 2013;8(8):e72179.
   PubMed Web of Science ®Google Scholar
• Lee YM, Kim JM, Lee HJ, et al. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas. Urol Oncol. 2019;37(10):742–748.
   PubMed Web of Science ®Google Scholar
• Lameirinhas A, Miranda-Goncalves V, Henrique R, et al. The complex interplay between metabolic reprogramming and epigenetic alterations in renal cell carcinoma. Genes (Basel). 2019;10(4): 264.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Shirvani-Farsani Z, Branicki W, et al. MicroRNA signature in renal cell carcinoma. Front Oncol. 2020;10:596359.
   PubMed Web of Science ®Google Scholar
• Carnero A. Spinophilin: a new tumor suppressor at 17q21. Curr Mol Med. 2012;12(5):528–535.
   PubMed Web of Science ®Google Scholar
• Krieg AJ, Rankin EB, Chan D, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol. 2010;30(1):344–353.
   PubMed Web of Science ®Google Scholar
• Ruan H, Yang H, Wei H, et al. Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition. Int J Oncol. 2017;51(1):336–346.
   PubMed Web of Science ®Google Scholar
• Na XY, Hu XQ, Zhao Y, et al. LncRNA DNAJC3-AS1 functions as oncogene in renal cell carcinoma via regulation of the miR-27a-3p/PRDM14 axis. Eur Rev Med Pharmacol Sci. 2021;25(3):1291–1301.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–1420.
   PubMed Web of Science ®Google Scholar
• Yang CY, Wang J, Zhang JQ, et al. Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway. Bioengineered. 2021;12(1):4432–4441.
   PubMed Web of Science ®Google Scholar
• Jin C, Shi L, Li Z, et al. Circ_0039569 promotes renal cell carcinoma growth and metastasis by regulating miR-34a-5p/CCL22. Am J Transl Res. 2019;11(8):4935–4945.
   PubMed Web of Science ®Google Scholar
• Zhai Z, Fu Q, Liu C, et al. Emerging roles of hsa-circ-0046600 targeting the miR-640/HIF-1α signalling pathway in the progression of HCC. Onco Targets Ther. 2019;12:9291–9302.
   PubMed Web of Science ®Google Scholar
• Tang C, Wang X, Ji C, et al. The role of miR-640: a potential suppressor in breast cancer via Wnt7b/β-catenin signaling pathway. Front Oncol. 2021;11:645682.
   PubMed Web of Science ®Google Scholar
• Xiang W, Han L, Mo G, et al. MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma. J Cell Biochem. 2020;121(2):1504–1513.
   PubMed Web of Science ®Google Scholar
• Bartolini A, Di Paolo D, Noghero A, et al. The neuronal pentraxin-2 pathway is an unrecognized target in human neuroblastoma, which also offers prognostic value in patients. Cancer Res. 2015;75(20):4265–4271.
   PubMed Web of Science ®Google Scholar
• Xu C, Tian G, Jiang C, et al. NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/beta-catenin pathway via FZD6. Cell Death Dis. 2019;10(3):217.
   PubMedGoogle Scholar
• Schrodter S, Braun M, Syring I, et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. Mol Cancer. 2016;15:10.
   PubMed Web of Science ®Google Scholar
• Eikrem O, Beisland C, Hjelle K, et al. Transcriptome sequencing (RNAseq) enables utilization of formalin-fixed, paraffin-embedded biopsies with clear cell renal cell carcinoma for exploration of disease biology and biomarker development. PloS One. 2016;11(2):e0149743.
   PubMed Web of Science ®Google Scholar
• Shukla S, Pia Patric IR, Thinagararjan S, et al. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-kappaB nexus. Cancer Res. 2013;73(22):6563–6573.
   PubMed Web of Science ®Google Scholar